The spread of SARs-CoV-2 variant Omicron has raised global attention recently. Vela Diagnostics, a subsidiary company under Luye Life Sciences Group that focuses on molecular diagnostics, has evaluate...
On November 29, 2021, 2021 (4th) Social Responsibility Conference was held in Shanghai. Luye Life Sciences Group was awarded “2021 Most Influential Brand of Social Responsibility” and “Sustainable ...
Boan Biotech, a subsidiary of Luye Pharma Group, announced today that it has signed a Memorandum of Understanding with Merck, a world-leading science and technology company, under which the two partie...
18 November 2021, Shanghai - Mindfront Health, the global mental service brand of Luye Medical Group opened a new outpatient center in Crystal Galleria, Jing’an CBD, Shanghai, China. Supported b...
November 15, 2021, Shanghai, China – Luye Pharma Group today announced that it has submitted the Investigational New Drug (IND) application for its innovative microspheres injection LY03009 in t...
October 13, 2021, Shanghai -- Luye Pharma Group announced that the marketing authorization application for the Denosumab Injection (LY06006 / BA6101), developed by Boan Biotech, a subsidiary of the Gr...
Luye Pharma Group today announced that BA1105, a novel antibody developed by its subsidiary Boan Biotech, has been approved by the Center for Drug Evaluation (CDE) of China's National Medical Prod...
Luye Pharma Group today announced that LY03015, a next-generation Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, has been approved by the Centre for Drug Evaluation (CDE) of China’s Nation...
Research results from a study into Luye Pharma’s in-house developed LY03015, a next-generation vesicular monoamine transporter 2 (VMAT2) inhibitor, were recently published in the European Journa...
September 27, 2021, Shanghai, China – Luye Pharma Group today announced that Dulaglutide Injection (BA5101) developed in-house by Boan Biotech, a subsidiary of the Group, has obtained approval f...
TOP